Skip to main content
Article thumbnail
Location of Repository

Medical bioremediation of age-related diseases

By Jacques M Mathieu, John Schloendorn, Bruce E Rittmann and Pedro JJ Alvarez

Abstract

Catabolic insufficiency in humans leads to the gradual accumulation of a number of pathogenic compounds associated with age-related diseases, including atherosclerosis, Alzheimer's disease, and macular degeneration. Removal of these compounds is a widely researched therapeutic option, but the use of antibodies and endogenous human enzymes has failed to produce effective treatments, and may pose risks to cellular homeostasis. Another alternative is "medical bioremediation," the use of microbial enzymes to augment missing catabolic functions. The microbial genetic diversity in most natural environments provides a resource that can be mined for enzymes capable of degrading just about any energy-rich organic compound. This review discusses targets for biodegradation, the identification of candidate microbial enzymes, and enzyme-delivery methods

Topics: Review
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2674406
Provided by: PubMed Central

Suggested articles

Citations

  1. (1990). 26-Hydroxycholesterol: synthesis, metabolism, and biologic activities.
  2. (1989). A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein.
  3. (2005). A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med
  4. (2005). A: Diabetic vascular disease: it's all the RAGE. Antioxid Redox Signal
  5. (1977). A: Novel routes for metabolism ofCholesterol 7-ketocholesterol alpha-hydroxylase. RejuvenationJ Lipid Res
  6. (2002). A: The mitochondrial-lysosomal axis theory of aging: accumulation of damaged mitochondria as a result of imperfect autophagocytosis.
  7. (2008). Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces A beta deposits in APP+PS1 transgenic mice. Molecular Therapy
  8. (2002). ADNJ: Bioremediation meets biomedicine: therapeutic translation of microbial catabolism to the lysosome. Trends in Biotechnology
  9. (2005). Advanced glycation endproducts – role in pathology of diabetic complications. Diabetes Res Clin Pract
  10. (2003). AE: Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther
  11. (2001). Age-related changes in protein oxidation and proteolysis in mammalian cells.
  12. (2008). AJ: Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Current Alzheimer Research
  13. (2005). Alkon DL: Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide.
  14. (1991). Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci
  15. (1991). Alteration of enzyme specificity and catalysis by protein engineering. Curr Opin Biotechnol
  16. (2008). Alvarez PJ: Microbial degradation of 7-ketocholesterol. Biodegradation
  17. (1988). AM: Extraction from Natural Planktonic Microorganisms of DNA Suitable for Molecular Biological Studies. Appl Environ Microbiol
  18. (2008). Amyloidbeta peptide degradation in cell cultures by mycoplasma contaminants.
  19. and 7-ketocholesterol in human atheromatous plaques. Biochim Biophys Acta
  20. (2001). Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord
  21. (1991). Argoff CE: Replacement therapy for inherited enzyme deficiency – macrophage-targeted glucocerebrosidase for Gaucher's disease.
  22. (1994). Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages.
  23. (1999). BG: Representational difference analysis of cDNA for the detection of differential gene expression in bacteria: development using a model of ironregulated gene expression in Neisseria meningitidis.
  24. (1993). Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages.
  25. (1999). Biochim Biophys Acta
  26. (1996). Bjorkhem I: Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA
  27. (1996). Blanchette-Mackie EJ: Intracellular trafficking of cholesterol monitored with a cyclodextrin.
  28. (1978). BM: Diet-induced arteriopathies in the rabbit aorta and oral vasculature. J Dent Res
  29. (1998). Brunk UT: On the degradability and exocytosis of ceroid/lipofuscin in cultured rat cardiac myocytes. Mech Ageing Dev
  30. (2000). C: The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. Invest Ophthalmol Vis Sci
  31. (2006). Catabolic insufficiency and aging.
  32. (1985). CB: Influence of cholesterol oxidation derivatives on membrane bound enzymes in cultured aortic smooth muscle cells. Proc Soc Exp Biol Med
  33. (2005). Cheng S: Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
  34. (2000). Cholesterol and oxysterol metabolism and subcellular distribution in macrophage foam cells. Accumulation of oxidized esters in lysosomes.
  35. (1998). Cholesterol homeostasis in human brain: turnover of 24Shydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation.
  36. (1993). Cloning the differences between two complex genomes. Science
  37. (2007). Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem Int
  38. (2000). Craik CS: Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci USA
  39. (2005). Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: an update on "a puzzle nearing resolution".
  40. (2007). CS: Prevention of 7-ketocholesterol-induced mitochondrial damage and cell death by calmodulin inhibition. Brain Res
  41. (2008). Cuervo AM: Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med
  42. (1999). Culture-independent identification of microorganisms that respond to specified stimuli. Appl Environ Microbiol
  43. (2004). Current concepts in the pathogenesis of agerelated macular degeneration. Arch Ophthalmol
  44. (1994). Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol. Arterioscler Thromb
  45. (2004). D'Azzo A: Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis.
  46. (2004). DB: Quantifying the accessibility of the metagenome by random expression cloning techniques. Environ Microbiol
  47. (1973). Dekaban AS: Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease.
  48. (1974). Dekaban AS: Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.
  49. (2003). DeMartino GN: Intracellular localization of proteasomes.
  50. (2000). Dice JF: Age-related decline in chaperone-mediated autophagy.
  51. (2005). DR: Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: an update on "a puzzle nearing resolution".
  52. (2001). E: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science
  53. (2008). E: Interaction of 7-ketocholesterol with two major components of the inner leaflet of the plasma membrane: phosphatidylethanolamine and phosphatidylserine. Biochemistry
  54. (2006). E: Oxidation of A2E results in the formation of highly reactive aldehydes and ketones. Photochem Photobiol
  55. (2000). Effect of collagen turnover on the accumulation of advanced glycation end products.
  56. (1998). EJ: Production and use of normalized DNA libraries.
  57. (2007). Eltis LD: A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc Natl Acad Sci USA
  58. (2006). Eltis LD: The complete genome of Rhodococcus sp. RHA1 provides insights into a catabolic powerhouse. Proc Natl Acad Sci USA
  59. (2005). Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging
  60. (2003). Enzymatic deglycation with amadoriase enzymes from Aspergillus sp. as a potential strategy against the complications of diabetes and aging. Biochem Soc Trans
  61. (2006). Enzyme replacement for lysosomal diseases. Annu Rev Med
  62. (1995). Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med
  63. (2007). Expression of a functional sphingomyelinase of Pseudomonas sp. TK4 in mammalian cells. Biosci Biotechnol Biochem
  64. (2006). Extracellular glycation crosslinks: prospects for removal. Rejuvenation Res
  65. (1952). EY: Biological effect of 7-ketocholesterol. Rev Can Biol
  66. (2003). F: The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol Sci
  67. (2005). Fogliano V: Substrate specificity of amadoriase I from Aspergillus fumigatus.
  68. (2008). FR: Degradation of fibrillar forms of Alzheimer's amyloid beta-peptide by macrophages. Neurobiol Aging
  69. (2003). Friguet B: Changes in rat liver mitochondria with aging. Lon protease-like reactivity and N(epsilon)-carboxymethyllysine accumulation in the matrix.
  70. (2008). G: Oxidation as a crucial reaction for cholesterol to induce tissue degeneration: CD36 overexpression in human promonocytic cells treated with a biologically relevant oxysterol mixture. Aging Cell
  71. (2001). Garbage catastrophe theory of aging: imperfect removal of oxidative damage? Redox Rep
  72. (2003). Gene function analysis in environmental isolates: the nif regulon of the strict iron oxidizing bacterium Leptospirillum ferrooxidans. Proc Natl Acad Sci USA
  73. (1999). Glabe CG: Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1-42. J Biol Chem
  74. (2005). Glucosepane is a major protein cross-link of the senescent human extracellular matrix. Relationship with diabetes.
  75. (2000). Glycation as the glucose link to diabetic complications.
  76. (2006). Glycation increases human annulus fibrosus stiffness in both experimental measurements and theoretical predictions.
  77. (2004). Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci USA
  78. (2004). Grabowski GA: Reduction of atherosclerotic plaques by lysosomal acid lipase supplementation. Arterioscler Thromb Vasc Biol
  79. (2006). Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res
  80. (2006). Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Therapy
  81. (1992). Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science
  82. (2007). HM: Oxysterols, cholesterol homeostasis, and Alzheimer disease.
  83. (2003). Hock C: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology
  84. (2008). Hoeben RC: How not to be seen: immune-evasion strategies in gene therapy. Gene Ther
  85. Horiuchi T: Purification and characterization of a new enzyme, N-alkylglycine oxidase from Cladosporium sp.
  86. (1987). Identification of mannose 6-phosphate and mannose receptors in dystrophic and normal retinal pigment epithelium. Prog Clin Biol Res
  87. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature
  88. (1999). Immunochemical detection and isolation of DNA from metabolically active bacteria. Appl Environ Microbiol
  89. (2007). Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
  90. (2004). Inhibition of the ATPdriven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2-E may contribute to the pathogenesis of age-related macular degeneration.
  91. (1999). Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell
  92. (2001). Iqbal K: Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA
  93. (1998). Isolation and onestep preparation of A2E and iso-A2E, fluorophores from human retinal pigment epithelium. Proc Natl Acad Sci USA
  94. (1987). JA: Engineering enzyme specificity by "substrate-assisted catalysis".
  95. (2008). JA: Longterm effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet
  96. (1984). Jr: George Lyman Duff memorial lecture. Persistent problems in the pathogenesis of atherosclerosis. Arteriosclerosis
  97. (1999). K: A2E, a lipofuscin fluorophore, in human retinal pigmented epithelial cells in culture. Invest Ophthalmol Vis Sci
  98. (1995). Kameda-Takemura K: Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects.
  99. (2001). Karsch KR: Alcohol enhances oxysterol-induced apoptosis in human endothelial cells by a calcium-dependent mechanism. Arterioscler Thromb Vasc Biol
  100. (1998). Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.
  101. (1995). KH: Phylogenetic identification and in situ detection of individual microbial cells without cultivation. Microbiol Rev
  102. (2009). Kishnani PS: Elimination of antibodies to recombinant enzyme in Pompe's disease.
  103. (1998). Kominami E: Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on 'calpain-cathepsin hypothesis'.
  104. (2000). Kritharides L: Metabolism of oxidized LDL by macrophages. Curr Opin Lipidol
  105. (2004). LaFerla FM: Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron
  106. (1996). Lagrost L: Induction of apoptosis in endothelial cells treated with cholesterol oxides.
  107. (2002). Langer T: Membrane protein degradation by AAA proteases in mitochondria. Biochim Biophys Acta
  108. (1985). Langmuir Blodgett Film Characteristics and Phospholipid Membrane Ion Conduction .1. Modification by Cholesterol and Oxidized Derivatives. Analytica Chimica Acta
  109. (2007). Leake DS: Low density lipoprotein undergoes oxidation within lysosomes in cells. Circ Res
  110. (2008). Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron
  111. (2004). Lipid oxidation in atherogenesis: an overview. Biochem Soc Trans
  112. (2000). LS: Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron
  113. (2005). LS: Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science
  114. (2003). Masliah E: Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.
  115. (2006). Mechanism of cholesterol transfer from the Niemann-Pick type C2 protein to model membranes supports a role in lysosomal cholesterol transport.
  116. (1992). Mechanism of degradation of the steroid side chain in the formation of bile acids.
  117. (2005). Medical bioremediation: prospects for the application of microbial catabolic diversity to aging and several major age-related diseases. Ageing Res Rev
  118. (2005). Metagenomic gene discovery: past, present and future. Trends Biotechnol
  119. (1995). MG: Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature
  120. (2001). Mitchinson MJ: Oxysterol profiles of normal human arteries, fatty streaks and advanced lesions. Free Radic Res
  121. (1977). Mitropoulos KA: Cholesterol 7 alpha-hydroxylase.
  122. (1984). Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA
  123. (1998). Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. Chem Biol
  124. (1999). Molecular composition of drusen as related to substructural phenotype.
  125. (2009). Molecular pathology of age-related macular degeneration. Prog Retin Eye Res
  126. (1979). MS: Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA
  127. Nalivaeva NN: Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. New York Acad Sciences;
  128. (2004). Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up.
  129. (2001). Nitsch RM: Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science
  130. (2004). Oparil S: Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
  131. (2006). Oxidative stress, accumulation of biological 'garbage', and aging. Antioxid Redox Signal
  132. (1996). Oxidized LDL Induces Apoptosis in Cultured Smooth Muscle Cells: A Possible Role for 7-Ketocholesterol. Biochemical and Biophysical Research Communications
  133. (2009). Oxysterol mixtures, in atheroma-relevant proportions, display synergisticMicrobial Cell Factories
  134. (1999). Oxysterols and atherosclerosis. Atherosclerosis
  135. (1996). P: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature
  136. (2005). Pardridge WM: Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther
  137. (2008). Pardridge WM: Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm Res
  138. (1998). PG: Lysosomal lipid accumulation from oxidized low density lipoprotein is correlated with hypertrophy of the Golgi apparatus and trans-Golgi network. J Lipid Res
  139. (2006). Phage-displayed antibodies for the detection of glycated proteasome in aging cells.
  140. (2006). Pownall HJ: Structures of biologically active oxysterols determine their differential effects on phospholipid membranes. Biochemistry
  141. (1998). Prokaryotes: the unseen majority.
  142. (2006). Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce "mammalianized" recombinant glycoproteins. Adv Virus Res
  143. (1983). Protein synthesis and degradation during aging and senescence. Biol Rev Camb Philos Soc
  144. (1987). Recruitment of substrate-specificity properties from one enzyme into a related one by protein engineering.
  145. (2003). Regulatory T cells in transplantation tolerance. Nat Rev Immunol
  146. (2008). Restoration of lysosomal pH in RPE cells from cultured human and ABCA4(-/-) mice: pharmacologic approaches and functional recovery. Invest Ophthalmol Vis Sci
  147. (2002). Rodriguez-Boulan E: The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium.
  148. (2006). Roncarolo MG: Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes
  149. (1992). RT: The intracellular storage and turnover of apolipoprotein B of oxidized LDL in macrophages. Biochim Biophys Acta
  150. (1999). S: Epidemiology of age-related macular degeneration. Mol Vis
  151. (2005). Salvayre R: Two distinct calcium-dependent mitochondrial pathways are involved in oxidized LDLinduced apoptosis. Arterioscler Thromb Vasc Biol
  152. (2003). Schaftingen E: Fructosamine 3-kinase, an enzyme involved in protein deglycation. Biochem Soc Trans
  153. (2002). Schaftingen E: Identification of a pathway for the utilization of the Amadori product fructoselysine in Escherichia coli.
  154. (2005). Schaftingen E: Identification of glucoselysine-6-phosphate deglycase, an enzyme involved in the metabolism of the fructation product glucoselysine.
  155. (2000). Schaftingen E: Identification, cloning, and heterologous expression of a mammalian fructosamine-3-kinase. Diabetes
  156. (2006). Schaftingen E: Increased protein glycation in fructosamine 3-kinase-deficient mice.
  157. (2005). Schenk D: Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron
  158. (2005). Sebekova K: Dietary bread crust advanced glycation end products bind to the receptor for AGEs in HEK-293 kidney cells but are rapidly excreted after oral administration to healthy and subtotally nephrectomized rats.
  159. (2000). Sevanian A: Lysosomal destabilization during macrophage damage induced by cholesterol oxidation products. Free Radic Biol Med
  160. (1996). Siebert PD: Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries.
  161. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications.
  162. (2005). Sparrow JR: Medical bioremediation: prospects for the application of microbial catabolic diversity to aging and several major age-related diseases. Ageing Res Rev
  163. (2005). Spyridopoulos I: Relevance and mechanism of oxysterol stereospecifity in coronary artery disease. Free Radic Biol Med
  164. (2000). Sterol 27-hydroxylase acts on 7-ketocholesterol in human atherosclerotic lesions and macrophages in culture.
  165. (1997). Structural modifications of proteins during aging.
  166. (1997). Structure and physiological function of calpains.
  167. (2008). Sunder-Plassmann G: Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta. Mol Genet Metab
  168. (2004). Suppressive subtractive hybridization as a tool for identifying genetic diversity in an environmental metagenome: the rumen as a model. Environ Microbiol
  169. (1997). T: A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature
  170. (1998). T: Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol
  171. (1996). T: Transient brain ischaemia provokes Ca2+, PIP2 and calpain responses prior to delayed neuronal death in monkeys.
  172. (2002). Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress.
  173. (2000). TeKoppele JM: Effect of collagen turnover on the accumulation of advanced glycation end products.
  174. (2005). Testing the "garbage" accumulation theory of ageing: mitotic activity protects cells from death induced by inhibition of autophagy. Biogerontology
  175. (1974). The ageing, growth and death of cells. Nature
  176. (1984). The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol
  177. (2004). The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci
  178. (1986). The pathogenesis of atherosclerosis – an update.
  179. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature
  180. (1997). The photoreceptor rim protein is an ABC transporter encoded by the gene for recessive Stargardt's disease (ABCR). FEBS Lett
  181. (2001). The role of AGEs in aging: causation or correlation. Exp Gerontol
  182. (1996). Tiedje JM: DNA recovery from soils of diverse composition.
  183. (2008). Tissue Transglutaminase, Protein Cross-linking and Alzheimer's Disease: Review and Views. Int J Clin Exp Pathol
  184. (2008). Tolerance and chimerism after renal and hematopoietic-cell transplantation.
  185. (2006). Tomatsu S: Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors. Proc Natl Acad Sci USA
  186. (2004). Topol E: Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet
  187. (2004). Tsai LH: Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med
  188. (1999). Tsai LH: Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature
  189. (1991). UP: Oxidized low density lipoprotein is resistant to cathepsins and accumulates within macrophages.
  190. (2000). VM: "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders.
  191. (1993). Water Science and Technology Board: In situ bioremediation: when does it work?
  192. (2006). Weiner HL: Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol
  193. (2005). WG: Aggregated LDL and lipid dispersions induce lysosomal cholesteryl ester accumulation in macrophage foam cells.
  194. (2007). WG: Effects of cellular cholesterol loading on macrophage foam cell lysosome acidification.
  195. (1998). WG: Lysosomal sequestration of free and esterified cholesterol from oxidized low density lipoprotein in macrophages of different species.
  196. (2001). Why don't graveyards fluoresce?Anti-aging applications of the bacterial degradation of lysosomal aggregates.
  197. (2006). Wiczkowski A: Cellular toxicity of oxycholesterols. Bioessays
  198. (1989). Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.
  199. (1984). Wong CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun
  200. (2007). Wraith JE: Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology
  201. (2008). Yee VC: Crystal structure of the deglycating enzyme fructosamine oxidase (amadoriase II).

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.